Alstoe launches chewable Tempora for heart failure - Zenopa Zenopa According to estimates, degenerative mitral valve disease is the underlying cause of 75 percent of chronic heart failure cases among canines, making Tempora a potentially important new therapy option. Earlier this year, Alstoe was acquired by French ... |
